Execs On The Move: April 2022
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
You may also be interested in...
Lupin has named a new head of compliance, emphasizing the importance of achieving the highest quality standards just weeks after the FDA notified the firm of observations following an inspection at its Indian facility in Tarapur.
Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.
Stockholm-based AI Medical Technology is developing Dermalyser, which can help doctor’s diagnose skin cancer using images of moles and lesions. The company is initially focused on Sweden and the Netherlands, but hopes to soon expand into new European markets and the US.